5626 related articles for article (PubMed ID: 21369647)
1. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
Gottlieb AB; Gordon K; Giannini EH; Mease P; Li J; Chon Y; Maddox J; Weng HH; Wajdula J; Lin SL; Baumgartner SW
J Drugs Dermatol; 2011 Mar; 10(3):289-300. PubMed ID: 21369647
[TBL] [Abstract][Full Text] [Related]
2. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
3. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
4. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.
van der Heijde D; Zack D; Wajdula J; Sridharan S; Koenig AS
Scand J Rheumatol; 2014; 43(1):49-53. PubMed ID: 24182312
[TBL] [Abstract][Full Text] [Related]
5. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience.
Moreland LW; Weinblatt ME; Keystone EC; Kremer JM; Martin RW; Schiff MH; Whitmore JB; White BW
J Rheumatol; 2006 May; 33(5):854-61. PubMed ID: 16541481
[TBL] [Abstract][Full Text] [Related]
6. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections.
Aggarwal R; Manadan AM; Poliyedath A; Sequeira W; Block JA
J Rheumatol; 2009 May; 36(5):914-7. PubMed ID: 19332623
[TBL] [Abstract][Full Text] [Related]
7. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
8. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.
Lebwohl M; Blum R; Berkowitz E; Kim D; Zitnik R; Osteen C; Wallis WJ
Arch Dermatol; 2005 Jul; 141(7):861-4. PubMed ID: 16027301
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
10. Etanercept: efficacy and safety for approved indications.
Kerensky TA; Gottlieb AB; Yaniv S; Au SC
Expert Opin Drug Saf; 2012 Jan; 11(1):121-39. PubMed ID: 22074366
[TBL] [Abstract][Full Text] [Related]
11. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
[TBL] [Abstract][Full Text] [Related]
13. Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database.
Gottlieb AB; Leonardi CL; Goffe BS; Ortonne JP; van der Kerkhof PC; Zitnik R; Nakanishi A; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S92-100. PubMed ID: 16488335
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Ilowite NT; Wallace CA; Chon Y; Lin SL; Baumgartner SW; Giannini EH;
Arthritis Rheum; 2008 May; 58(5):1496-504. PubMed ID: 18438876
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
16. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism.
Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Davis JC; van der Heijde DM; Braun J; Dougados M; Clegg DO; Kivitz AJ; Fleischmann RM; Inman RD; Ni L; Lin SL; Tsuji WH
Ann Rheum Dis; 2008 Mar; 67(3):346-52. PubMed ID: 17967833
[TBL] [Abstract][Full Text] [Related]
18. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
19. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.
van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG
Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147
[TBL] [Abstract][Full Text] [Related]
20. Managing pediatric patients with psoriasis.
Bard S; Torchia D; Schachner LA
Am J Clin Dermatol; 2010; 11 Suppl 1():15-7. PubMed ID: 20586500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]